Serafin Andrew 4
4 · Harmony Biosciences Holdings, Inc. · Filed Dec 5, 2022
Insider Transaction Report
Form 4
Serafin Andrew
CHIEF STRATEGY OFFICER
Transactions
- Exercise/Conversion
Stock Option
2022-12-02−38,000→ 83,729 totalExercise: $8.22Exp: 2027-10-01→ Common Stock (38,000 underlying) - Sale
Common Stock
2022-12-02$60.12/sh−37,080$2,229,246→ 920 total - Exercise/Conversion
Common Stock
2022-12-02$8.22/sh+38,000$312,360→ 38,000 total - Sale
Common Stock
2022-12-02$60.71/sh−920$55,854→ 0 total
Footnotes (4)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.67 to $60.66. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.67 to $60.77. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The stock options vests in five equal annual installments beginning on October 1, 2018.